GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaEngine Inc (ROCO:4162) » Definitions » 3-Year FCF Growth Rate

PharmaEngine (ROCO:4162) 3-Year FCF Growth Rate : -21.00% (As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is PharmaEngine 3-Year FCF Growth Rate?

PharmaEngine's Free Cash Flow per Share for the three months ended in Dec. 2024 was NT$0.84.

During the past 12 months, PharmaEngine's average Free Cash Flow per Share Growth Rate was 77.30% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -21.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 74.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of PharmaEngine was 133.00% per year. The lowest was -73.60% per year. And the median was 19.40% per year.


Competitive Comparison of PharmaEngine's 3-Year FCF Growth Rate

For the Biotechnology subindustry, PharmaEngine's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaEngine's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaEngine's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where PharmaEngine's 3-Year FCF Growth Rate falls into.


;
;

PharmaEngine 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


PharmaEngine  (ROCO:4162) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


PharmaEngine 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of PharmaEngine's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaEngine Business Description

Traded in Other Exchanges
N/A
Address
10 Minsheng East Road, 11th Floor, Section 3, Taipei, TWN, 104
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its projects pipeline are: ONIVYDE was approved by the U.S. FDA, Taiwan FDA, and EMA for patients with gemcitabine-treated metastatic pancreatic cancer; and PEP07. It generates the revenue from Sales of goods.

PharmaEngine Headlines

No Headlines